GONUTS has been updated to MW1.31 Most things seem to be working but be sure to report problems.

Have any questions? Please email us at ecoliwiki@gmail.com


Jump to: navigation, search


You don't have sufficient rights on this wiki to edit tables. Perhaps you need to log in. Changes you make in the Table editor will not be saved back to the wiki

See Help for Help on this wiki. See the documentation for how to use the table editor


Sen, U, Tyagi, N, Patibandla, PK, Dean, WL, Tyagi, SC, Roberts, AM and Lominadze, D (2009) Fibrinogen-induced endothelin-1 production from endothelial cells. Am. J. Physiol., Cell Physiol. 296:C840-7


We previously demonstrated that fibrinogen (Fg) binding to the vascular endothelial intercellular adhesion molecule-1 (ICAM-1) leads to microvascular constriction in vivo and in vitro. Although a role of endothelin-1 (ET-1) in this Fg-induced vasoconstriction was suggested, the mechanism of action was not clear. In the current study, we tested the hypothesis that Fg-induced vasoconstriction results from ET-1 production by vascular endothelial cells (EC) and is mediated by activation of extracellular signal-regulated kinase -1/2 (ERK-1/2). Confluent, rat heart microvascular endothelial cells (RHMECs) were treated with one of the following: Fg (2 or 4 mg/ml), Fg (4 mg/ml) with ERK-1/2 kinase inhibitors (PD-98059 or U-0126), Fg (4 mg/ml) with an antibody against ICAM-1, or medium alone for 45 min. The amount of ET-1 formed and the concentration of released von Willebrand factor (vWF) in the cell culture medium were measured by ELISAs. Fg-induced exocytosis of Weibel-Palade bodies (WPBs) was assessed by immunocytochemistry. Phosphorylation of ERK-1/2 was detected by Western blot analysis. Fg caused a dose-dependent increase in ET-1 formation and release of vWF from the RHMECs. This Fg-induced increase in ET-1 production was inhibited by specific ERK-1/2 kinase inhibitors and by anti-ICAM-1 antibody. Immunocytochemical staining showed that an increase in Fg concentration enhanced exocytosis of WPBs in ECs. A specific endothelin type B receptor blocker, BQ-788, attenuated the enhanced phosphorylation of ERK-1/2 in ECs caused by increased Fg content in the culture medium. The presence of an endothelin converting enzyme inhibitor, SM-19712, slightly decreased Fg-induced phosphorylation of ERK-1/2, but inhibited production of Fg-induced ET-1 production. These results suggest that Fg-induced vasoconstriction may be mediated, in part, by activation of ERK-1/2 signaling and increased production of ET-1 that further increases EC ERK-1/2 signaling. Thus, an increased content of Fg may enhance vasoconstriction through increased production of ET-1.


PubMed PMC2670653 Online version:10.1152/ajpcell.00515.2008


Animals; Aspartic Acid Endopeptidases/antagonists & inhibitors; Aspartic Acid Endopeptidases/metabolism; Butadienes/pharmacology; Cells, Cultured; Coronary Vessels/metabolism; Endothelial Cells/drug effects; Endothelial Cells/enzymology; Endothelial Cells/metabolism; Endothelin B Receptor Antagonists; Endothelin-1/metabolism; Exocytosis; Fibrinogen/metabolism; Flavonoids/pharmacology; Humans; Intercellular Adhesion Molecule-1/metabolism; Metalloendopeptidases/antagonists & inhibitors; Metalloendopeptidases/metabolism; Microvessels/metabolism; Mitogen-Activated Protein Kinase 1/antagonists & inhibitors; Mitogen-Activated Protein Kinase 1/metabolism; Mitogen-Activated Protein Kinase 3/antagonists & inhibitors; Mitogen-Activated Protein Kinase 3/metabolism; Nitriles/pharmacology; Oligopeptides/pharmacology; Phosphorylation; Piperidines/pharmacology; Protein Kinase Inhibitors/pharmacology; Rats; Receptor, Endothelin B/metabolism; Sulfonamides/pharmacology; Sulfonylurea Compounds/pharmacology; Vasoconstriction; Weibel-Palade Bodies/metabolism; von Willebrand Factor/metabolism